SpringerLink
Log in

Estramustine : quelle place en 2010 dans le cancer du sein métastatique ?

Estramustine: what is its place in 2010 in metastatic breast cancer?

  • Mise Au Point / Update
  • Published:
Oncologie

Abstract

Management of breast cancer remains difficult, especially in themetastatic phase. Estramustine may represent an additional therapeutic option, due to an appropriate mechanism of action and significant results in phase II trials: an objective response was obtained in 17.5–47% of cases, with estramustine alone or in combination with docetaxel in advanced metastatic cancers. In addition, estramustine is administered orally and its cost is low. Further studies are mandatory to assess this drug in association with targeted therapies and optimize the benefit/risk ratio, in defining the best prophylactic strategy to decrease the incidence of thrombotic events.

Résumé

Le cancer du sein continue à poser des problèmes de prise en charge, notamment au stade métastatique. L’estramustine (EM) fait partie des molécules qui peuvent élargir la gamme des options thérapeutiques, en raison d’un rationnel pharmacologique pertinent et de résultats encourageants obtenus au cours d’études de phase II, en monothérapie ou en association au docétaxel, dans des cancers métastatiques (taux de réponse objective compris entre 17,5 et 47 %). De plus, cette molécule a l’avantage d’être administrée par voie orale, avec un coût faible. Des études sont nécessaires pour évaluer l’EM en association aux thérapies ciblées et optimiser le rapport bénéfice/risque en définissant la meilleure stratégie de prévention des accidents thromboemboliques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Alexander NC, Hancock AK, Masood MB, et al. (1979) Estracyt in advanced carcinoma of the breast: a phase II study. Clin Radiol 30(2): 139–47

    Article  PubMed  CAS  Google Scholar 

  2. Antoine EC (2006) Cancer du sein métastatique. Réflexions stratégiques sur la prise en charge de la chimiothérapie de première ligne. Oncologie 8: 36–50

    Article  CAS  Google Scholar 

  3. Bjork P, Borg A, Ferno M, et al. (1991) Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma. Anticancer Res 11(3): 1173–82

    PubMed  CAS  Google Scholar 

  4. Catapano CV, Carbone GM, Fernandes DJ (1996) The nuclear matrix as a target for cancer therapy. Ann Oncol 7(7): 659–66

    PubMed  CAS  Google Scholar 

  5. Dahllof B, Billstrom A, Cabral F, et al. (1993) Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53(19): 4573–81

    PubMed  CAS  Google Scholar 

  6. Dufresne A, Pivot X, Tournigand C, et al. (2008) Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107(2): 275–9

    Article  PubMed  CAS  Google Scholar 

  7. Eklov S, Mahdy E, Wester K, et al. (1996) Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest. Anticancer Res 16(4A): 1819–22

    PubMed  CAS  Google Scholar 

  8. Ferno M, Borg A, Idvall I (1987) Estramustine binding site in human breast cancer biopsy samples. Its relation to estrogen and progesterone receptor levels, age and menopausal status. Eur J Cancer Clin Oncol 23(10): 1505–10

    Article  PubMed  CAS  Google Scholar 

  9. Fizazi K, Le Maitre A, Hudes G, et al. (2007) Addition of estramustine to chemotherapy and survival of patients with castrationrefractory prostate cancer: a metaanalysis of individual patient data. Lanc Oncol 8(11): 994–1000

    Article  CAS  Google Scholar 

  10. Fredholm B (1974) Effects of estramustine phosphate on growth of DMBA induced mammary tumors in rats. Acta Pharmacol Toxicol 35(Suppl 1)

  11. Garcia AA, Keren-Rosenberg S, Parimoo D, et al. (1998) Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. J Clin Oncol 16(9): 2959–63

    PubMed  CAS  Google Scholar 

  12. Groupe européen du cancer du sein (1969) Essai clinique du phénol bis (2-chloroéthyle) carbamate d’estradiol dans le cancer mammaire en phase avancée. Eur J Cancer 5: 1–4

    Google Scholar 

  13. Institut national du cancer (2009) La situation du cancer en France. Database on the Internet: www.e-cancer.fr

  14. InVS (2008) Taux de participation au programme de dépistage organisé du cancer du sein 2006–2007. Available from: http://www.invs.sante.fr/presse/2008/le_point_sur/depistage_cancer_sein_070408/index.html

  15. Keren-Rosenberg S, Muggia FM (1997) Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study. Semin Oncol 24(1 Suppl 3): S26–S9

    PubMed  CAS  Google Scholar 

  16. Lubiniecki GM, Berlin JA, Weinstein RB, et al. (2004) Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormonerefractory prostate carcinoma: results of a meta-analysis. Cancer 101(12): 2755–9

    Article  PubMed  CAS  Google Scholar 

  17. Matsuoka H, Sugimachi K, Tomoda H, et al. (1995) Growth inhibitory effect of estrogen conjugated drugs against primary cultured breast cancer cells. Anticancer Res 15(4): 1289–96

    PubMed  CAS  Google Scholar 

  18. Pavelic J, Zgradic I, Pavelic K (1991) Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro. J Cancer Res Clin Oncol 117(3): 244–8

    Article  PubMed  CAS  Google Scholar 

  19. Perry CM, McTavish D (1995) Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7(1): 49–74

    Article  PubMed  CAS  Google Scholar 

  20. Ryu S, Gabel M, Khil MS, et al. (1994) Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30(1): 99–104

    PubMed  CAS  Google Scholar 

  21. Soule SE, Miller KD, Porcu P, et al. (2002) Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Ann Oncol 13(10): 1612–5

    Article  PubMed  CAS  Google Scholar 

  22. Speicher LA, Barone LR, Chapman AE, et al. (1994) P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86(9): 688–94

    Article  PubMed  CAS  Google Scholar 

  23. Tiersten AD, Nelsen C, Talbot S, et al. (2003) A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 97(3): 537–44

    Article  PubMed  CAS  Google Scholar 

  24. Wada T, Morikawa E, Houjou T, et al. (1990) Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers. Gan To Kagaku Ryoho 17(9): 1901–4

    PubMed  CAS  Google Scholar 

  25. Yang CP, Shen HJ, Horwitz SB (1994) Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86(9): 723–5

    Article  PubMed  CAS  Google Scholar 

  26. Zelek L, Barthier S, Riofrio M, et al. (2001) Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. Ann Oncol 12(9): 1265–8

    Article  PubMed  CAS  Google Scholar 

  27. Zerbib M (2009) Estramustin and prostate cancer: back to the future. La lettre du cancérologue (Mai 2009)

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale, centre Alexis-Vautrin, avenue de Bourgogne, F-54511, Vandoeuvre-lès-Nancy cedex, France

    E. Luporsi

  2. Département de cancérologie médicale, centre Léon-Bérard, 28, rue Laënnec, F-69373, Lyon cedex 08, France

    J.-P. Guastalla

  3. Département d’oncologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, F-75908, Paris cedex 15, France

    J. Médioni

  4. Namer Cancer Consulting, 472, route de Bellet, F-06200, Nice-Mougins, France

    M. Namer

  5. Service de pathologie mammaire, institut Gustave-Roussy, 39, rue Camille-Desmoulins, F-94805, Villejuif cedex, France

    M. Spielmann

  6. Service d’oncologie, hôpital américain, 63, boulevard Victor-Hugo, F-92202, Neuilly-sur-Seine cedex, France

    A. Toledano

  7. Service de cancérologie, hôpital Tenon, 4, rue, de la Chine, F-75970, Paris Cedex 20, France

    J. Gligorov

  8. Service d’oncologie, clinique Sainte-Anne, 184, route de la Wantzenau, F-67000, Strasbourg, France

    L.-M. Dourthe

Authors
  1. E. Luporsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.-P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Médioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Namer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Spielmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Toledano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L.-M. Dourthe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Luporsi.

About this article

Cite this article

Luporsi, E., Guastalla, JP., Médioni, J. et al. Estramustine : quelle place en 2010 dans le cancer du sein métastatique ?. Oncologie 12, 341–348 (2010). https://doi.org/10.1007/s10269-010-1886-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-010-1886-7

Keywords

Mots clés

Search

Navigation